Evolus: A Difficult 2025 Means I'm Downgrading Stock To 'Hold' For 2026
Summarize this article with:
Edmund InghamInvesting Group LeaderFollow5ShareSavePlay(12min)CommentsSummaryEvolus (EOLS) is downgraded to 'Hold' as competitive pressures, cash constraints, and missed targets cloud its 2026 outlook.EOLS maintains long-term guidance of $700m revenue and 20% operating margin by 2028, but management will reassess targets early next year.Q3 revenues grew 13% YoY to $69m, but net losses persist and cash burn threatens liquidity by end-2026 if profitability is not achieved.Jeuveau gains market share and Evolysse shows early synergy, yet fierce competition and high SG&A expenses limit near-term upside. Heri Harmono/iStock via Getty Images Investment Overview I've covered Evolus (EOLS), the Newport Beach, California-headquartered medical aesthetics company, in three prior notes for Seeking Alpha, in March 2024, January this year, and most recently in This article was written byEdmund Ingham14.45K FollowersFollowEdmund Ingham is a biotech consultant. He has been covering biotech, healthcare, and pharma for over 5 years, and has put together detailed reports of over 1,000 companies. He leads the investing group Haggerston BioHealth. The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts for all the Big Pharmas, forecasting, integrated financial statements, discounted cash flow analysis and market by market analysis. Learn more.Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.